These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19919639)

  • 1. Editorial Comment to Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment.
    Homma Y
    Int J Urol; 2010 Jan; 17(1):74. PubMed ID: 19919639
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Intravesical prostatic protrusion (IPP) and uroflowmetry in the management of benign prostatic enlargement (BPE).
    Foo KT; Lee LS
    Int J Urol; 2010 Jun; 17(6):589. PubMed ID: 20438589
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment.
    Lee LS; Sim HG; Lim KB; Wang D; Foo KT
    Int J Urol; 2010 Jan; 17(1):69-74. PubMed ID: 19919641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment.
    Kaplan SA
    J Urol; 2011 Apr; 185(4):1386-7. PubMed ID: 22098978
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Keqin z, et al. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement (Urology 2007;70:1096-1099).
    Chung SD; Chiu B; Yu HJ
    Urology; 2009 Jan; 73(1):216. PubMed ID: 19111744
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
    Speakman M; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; Lowe F; O'Leary M; Perez M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
    Prostate Cancer Prostatic Dis; 2005; 8(4):369-74. PubMed ID: 16130013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder weight and detrusor thickness as parameters of progression of benign prostatic hyperplasia.
    Tubaro A; Mariani S; De Nunzio C; Miano R
    Curr Opin Urol; 2010 Jan; 20(1):37-42. PubMed ID: 19901837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention.
    Christensen MM; Bruskewitz RC
    Urol Clin North Am; 1990 Aug; 17(3):509-16. PubMed ID: 1695779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etiology, epidemiology, and natural history of benign prostatic hyperplasia.
    Bushman W
    Urol Clin North Am; 2009 Nov; 36(4):403-15, v. PubMed ID: 19942041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
    Lowe FC; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; O'Leary M; Perez M; Speakman M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
    Prostate Cancer Prostatic Dis; 2005; 8(3):206-9. PubMed ID: 15953934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical therapy of benign prostatic hyperplasia].
    Altarac S
    Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ultrastructural studies of the detrusor in patients with benign prostatic hyperplasia].
    Loran OB; Vishnevskiĭ AE; Sekamova SM
    Urol Nefrol (Mosk); 1996; (4):27-31. PubMed ID: 8928345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of MR imaging and urodynamic findings in benign prostatic hyperplasia.
    Alam AM; Sugimura K; Okizuka H; Ishida J; Igawa M
    Radiat Med; 2000; 18(2):123-8. PubMed ID: 10888045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the measurement of intravesical prostatic protrusion predict the response to medical treatment in patients with benign prostatic hyperplasia? Lights and shadows.
    Alcántara Montero A; López de Alda González A
    Actas Urol Esp (Engl Ed); 2018 Oct; 42(8):542-543. PubMed ID: 29650470
    [No Abstract]   [Full Text] [Related]  

  • 16. [Benign prostatic hyperplasia--an old disease picture--from a new viewpoint].
    Hartung R
    Urologe A; 1995 Mar; 34(2):77-83. PubMed ID: 7538713
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement.
    Meuleman EJ
    Eur Urol; 2007 Oct; 52(4):1193-4. PubMed ID: 17293024
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benign prostatic hyperplasia].
    Huland H; Hartung R
    Urologe A; 1995 Jan; 34(1):1-2. PubMed ID: 7533446
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.